Temodar: References
Braintumor Website

Temodal Reference List

1.   Newlands, E.S., M.F.G. Stevens, S.R. Wedge, R.T. Wheelhouse, and C. Brock.
  Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews 23: 35-61, 1997.
2.   Krauseneck, P.
  Standards and recent advances in neuro-oncology. Aktuelle Neurologie 25: 219-226, 1998.
3.   Beijnen, J.H., K.P. Flora, G.W. Halbert, R.E. Henrar, and J.A. Slack.
  CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. British Journal of Cancer 72: 210-218, 1995.
4.   Weiss, G.R., H.A. Burris, S.G. Eckhardt, G.I. Rodriguez, S. Sharma, and A. Valley.
  New anticancer agents. [Review] [89 refs]. Cancer Chemotherapy & Biological Response Modifiers 17: 178-194, 1997.
5.   Armand, J.P.
  New anticancer drugs in Europe. [Review] [120 refs]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 24 Suppl 1: 70-93, 1997.
6.   Workman, P., S.B. Kaye, and G. Schwartsmann.
  Laboratory and phase I studies of new cancer drugs [published erratum appears in Curr Opin Oncol 1993 Mar;5(2):434]. [Review] [60 refs]. Current Opinion in Oncology 4: 1065-1072, 1992.
7.   Berger, N.A.
  Alkylating agents. [Review] [55 refs]. Cancer Chemotherapy & Biological Response Modifiers 15: 32-43, 1994.
8.   Stevens, M.F.G. and E.S. Newlands.
  From triazines and triazenes to temozolomide. European Journal of Cancer 29A: 1045-1047, 1993.
9.   Wang, W.F. and M.F.G. Stevens.
  Antitumor imidazotetrazines .35. New synthetic routes to the antitumor drug temozolomide. Journal of Organic Chemistry 62: 7288-7294, 1997.
10.   Wang, W.F., P.R. Lowe, W.T. Thomson, J. Clark, and M.F.G. Stevens.
  A new route to the antitumour drug temozolomide, but not thiotemozolomide. Chemical Communications 363-364, 1997.
11.   Wheelhouse, R.T., D.E.V. Wilman, W. Thomson, and M.F.G. Stevens.
  Antitumor imidazotetrazines.31. The synthesis of isotopically labelled temozolomide and a multinuclear (H-1,C-13,N-15) magnetic-resonance investigation of temozolomide and mitozolomide. Journal of the Chemical Society - Perkin Transactions 249-252, 1995.
12.   Wang, W.F., M.F.G. Stevens, W.T. Thomson, and B.P. Shutts.
  Antitumour imidazotetrazines .33.New syntheses of the antitumour drug temozolomide using masked methyl isocyanates. Journal of the Chemical Society - Perkin Transactions 2783-2787, 1995.
13.   Wang, Y.F., R.T. Wheelhouse, L.X. Zhao, D.F. Langnel, and M.F.G. Stevens.
  Antitumour imidazotetrazines. Part 36. Conversion of 5- aminoimidazole-4-carboxamide to imidazo[5,1-d][1,2,3,5]tetrazin- 4(3H)-ones and imidazo[1,5-a][1,3,5]triazin-4(3H)-ones related in structure to the antitumour agents temozolomide and mitozolomide. Journal of the Chemical Society - Perkin Transactions 1669-1675, 1998.
14.   Peori, M.B., K. Vaughan, and D.L. Hooper.
  Synthesis and characterization of novel bis-triazenes: 3,8-di[2-aryl- 1-azenyl]-1,3,6,8-tetraazabicyclo[4.4.1]undecanes and 1,3-di-2-[(4- methoxyphenyl)-1-diazenyl]imidazolidine. The reaction of diazonium ions with ethylenediamine/formaldehyde mixtures. Journal of Organic Chemistry 63: 7437-7444, 1998.
15.   Clark, A.S., B. Deans, M.F.G. Stevens, M.J. Tisdale, R.T. Wheelhouse, B.J. Denny, and J.A. Hartley.
  . Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. Journal of Medicinal Chemistry 38: 1493-1504, 1995.
16.   Wang, Y.F. and M.F.G. Stevens.
  Synthetic studies of 8-carbamoylimidazo-[5,1-d]1,2,3,5-tetrazin- 4(3H)-one: A key derivative of antitumour drug temozolomide. Bioorganic & Medicinal Chemistry Letters 6: 185-188, 1996.
17.   Lowe, P.R., C.E. Sansom, C.H. Schwalbe, M.F.G. Stevens, and A.S. Clark.
  Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC. Journal of Medicinal Chemistry 35: 3377-3382, 1992.
18.   Clark, A.S., M.F.G. Stevens, C.E. Sansom, and C.H. Schwalbe.
  Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA. Anti-Cancer Drug Design 5: 63-68, 1990.
19.   Williams, C.I., M.A. Whitehead, and B.J. JeanClaude.
  Equilibrium geometries and enantiomeric interconversions in tetrazepinone ring systems - A molecular mechanics, semiempirical and ab initio treatment. Theochem-Journal of Molecular Structure 392: 27-42, 1997.
20.   Mizuno, N.S. and R.W. Decker.
  Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide(NSC-407347). Biochem Pharmacol 25: 2643-2647, 1976.
21.   Denny, B.J., R.T. Wheelhouse, M.F.G. Stevens, L.L. Tsang, and J.A. Slack.
  . NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051, 1994.
22.   Tsang, L.L., C.P. Quarterman, A. Gescher, and J.A. Slack.
  Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemotherapy & Pharmacology 27: 342-346, 1991.
23.   Williams, C.I., M.A. Whitehead, and B.J. JeanClaude.
  A semiempirical PM3 treatment of benzotetrazepinone decomposition in acid media. Journal of Organic Chemistry 62: 7006-7014, 1997.
24.   Wilman, D.E.
  Prodrugs in cancer chemotherapy. Biochemical Society Transactions 14: 375-382, 1986.
25.   Shen, F., L.A. Decosterd, M. Gander, S. Leyvraz, J. Biollax, and F. Lejeune.
  . Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. Journal of Chromatography B: Biomedical Applications 667: 291-300, 1995.
26.   Kim, H.K., C.C. Lin, D. Parker, J. Veals, J. Lim, P. Likhari, P. Statkevich, A. Marco, and A.A. Nomeir.
  High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. Journal of Chromatography B, Biomedical Sciences & Applications. 703: 225-233, 1997.
27.   Artemov, D., Z.M. Bhujwalla, R.J. Maxwell, J.R. Griffiths, I.R. Judson, M.O. Leach, and J.D. Glickson.
  . Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. Magnetic Resonance in Medicine 34: 338-342, 1995.
28.   Ma, J. and J.M. Gallo.
  Delivery of cytotoxic drugs from carrier cells to tumour cells by apoptosis. Apoptosis 3: 195-202, 1998.
29.   Meikle, S.R., J.C. Matthews, C.S. Brock, P. Wells, R.J. Harte, V.J. Cunningham, T. Jones, and P. Price.
  . Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemotherapy & Pharmacology 42: 183-193, 1998.
30.   Stevens, M.F.G., J.A. Hickman, S.P. Langdon, D. Chubb, L. Vickers, R. Stone, Baig, C. Goddard, N.W. Gibson, and J.A. Slack.
  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Research 47: 5846-5852, 1987.
31.   Reid, J.M., D.C. Stevens, J. Rubin, and M.M. Ames.
  Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clinical Cancer Research 3: 2393-2398, 1997.
32.   Tsang, L.L., P.B. Farmer, A. Gescher, and J.A. Slack.
  . Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemotherapy & Pharmacology 26: 429-436, 1990.
33.   Lowe, P.R. and C.H. Schwalbe.
  DCMCIT, an analogue of the antitumour drugs mitozolomide and temozolomide. Acta Crystallographica - Section C - Crystal Structure Communications 50: 1629-1631, 1994.
34.   Jean-Claude, B.J., A. Mustafa, N.D. Cetateanu, Z. Damian, M.J. De, R. Yen, D. Vasilescu, T.H. Chan, and B. Leyland-Jones .
  Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro. British Journal of Cancer 76: 467-473, 1997.
35.   Jean-Claude, B.J., A. Mustafa, Z. Damian, J. DeMarte, D.E. Vasilescu, R. Yen, T.H. Chan, and B. LeylandJones.
  . Comparative studies between the effects of mitozolomide and two novel tetrazepinones PYRCL and QUINCL on NIH:OVCAR-3 cells. Cancer Chemotherapy and Pharmacology 42: 59-67, 1998.
36.   D'Incalci, M., P. Taverna, E. Erba, S. Filippeschi, D. Potenza, L. Mariani, L. Citti, and C.V. Catapano.
  O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Research 11: 115-121, 1991.
37.   Marzolini, C., L.A. Decosterd, F. Shen, M. Gander, S. Leyvraz, J. Bauer, T. Buclin, J. Biollaz, and F. Lejeune.
  Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemotherapy and Pharmacology 42: 433-440, 1998.
38.   Chinnasamy, N., J.A. Rafferty, I. Hickson, J. Ashby, H. Tinwell, G.P. Margison, T.M. Dexter, and L.J. Fairbairn.
  O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89: 1566-1573, 1997.
39.   Statkevich, P., I. Judson, D. Cutler, M. Dugan, M. Salfi, V. Batra, and P. Reidenberg
  Effect of ranitidine (R) on the pharmacokinetics (PK) of temozolomide (T). Clin Pharm & Ther 61: I47- (Abstract PI-39)1997.
40.   Dive, C., P. Workman, and J.V. Watson.
  Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry. Cancer Chemotherapy & Pharmacology 25: 149-155, 1989.
41.   Hooper, N.I., M.J. Tisdale, and P.J. Thornalley.
  Glyoxalase activity during differentiation of human leukaemia cells in vitro. Leukemia Research 11: 1141-1148, 1987.
42.   Karran, P. and R. Hampson.
  Genomic instability and tolerance to alkylating agents. [Review] [38 refs]. Cancer Surveys 28: 69-85, 1996.
43.   Bull, V.L. and M.J. Tisdale
  Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones. Biochemical Pharmacology 36: 3215-3220, 1987.
44.   Imperatori, L., G. Damia, P. Taverna, E. Garattini, L. Citti, L. Boldrini, and M. D'Incalci.
  3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis 15: 533-537, 1994.
45.   Zucchetti, M., C.V. Catapano, S. Filippeschi, E. Erba, and M. D'Incalci.
  . Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. Biochemical Pharmacology 38: 2069-2075, 1989.
46.   Tisdale, M.J.
  Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones. Biochemical Pharmacology 38: 1097-1101, 1989.
47.   Tisdale, M.J.
  Antitumour imidazotetrazines-X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045; M & B 39831; NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562. Biochemical Pharmacology 35: 311-316, 1986.
48.   Tisdale, M.J.
  Antitumour imidazotetrazines and gene expression. Acta Oncologica 27: 511-516, 1988.
49.   Catapano, C.V., M. Broggini, E. Erba, M. Ponti, L. Mariani, L. Citti, and D'Incalci.
  In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Research 47: 4884-4889, 1987.
50.   Tisdale, M.J.
  Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochemical Pharmacology 36: 457-462, 1987.
51.   Taverna, P., C.V. Catapano, L. Citti, M. Bonfanti, and M. D'Incalci.
  Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anti-Cancer Drugs 3: 401-405, 1992.
52.   Lee, S.M., N. Thatcher, D. Crowther, and G.P. Margison.
  Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Brit Journal of Cancer 69: 452-456, 1994.
53.   Baer, J.C., A.A. Freeman, E.S. Newlands, A.J. Watson, J.A. Rafferty, and G.P. Margison.
  Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. British Journal of Cancer 67: 1299-1302, 1993.
54.   Mitchell, R.B. and M.E. Dolan.
  Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy & Pharmacology 32: 59-63, 1993.
55.   Lacal, P.M., S. D'Atri, L. Orlando, E. Bonmassar, and G. Graziani.
  In vitro inactivation of human O6-alkylguanine DNA alkyltransferase by antitumor triazene compounds. J Pharm & Expt Ther 279: 416-422, 1996.
56.   Tentori, L., L. Orlando, P.M. Lacal, E. Benincasa, I. Faraoni, E. Bonmassar, S. D'Atri, and G. Graziani.
  Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Molecular Pharm 52: 249-258, 1997.
57.   Wang, G., C. Weiss, P. Sheng, and E. Bresnick.
  Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochemical Pharmacology 51: 1221-1228, 1996.
58.   Graziani, G., I. Faraoni, U. Grohmann, R. Bianchi, L. Binaglia, G.P. Margison, A.J. Watson, L. Orlando, E. Bonmassar, and S. D'Atri.
  O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Research 55: 6231-6236, 1995.
59.   Tentori, L., G. Graziani, S. Gilberti, P.M. Lacal, E. Bonmassar, and S. D'Atri.
  Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 9: 1888-1895, 1995.
60.   Jackson, P.E., C.N. Hall, P.J. OConnor, D.P. Cooper, G.P. Margison, and A.C. Povey.
  Low O-6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing a GC->AT transition in the K-ras oncogene. Carcinogenesis 18: 1299-1302, 1997.
61.   Belanich, M., T. Randall, M.A. Pastor, J.T. Kibitel, L.G. Alas, M.E. Dolan, Schold, S.C. Jr, M. Gander, F.J. Lejeune, B.F. Li, A.B. White, P. Wasserman, M.L. Citron, and D.B. Yarosh.
  . Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemotherapy & Pharmacology 37: 547-555, 1996.
62.   Bianchi, R., L. Citti, R. Beghetti, L. Romani, M. D'Incalci, P. Puccetti, and M.C. Fioretti.
  O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. Cancer Chemotherapy & Pharmacology 29: 277-282, 1992.
63.   Gerson, S.L., W. Phillips, M. Kastan, L.L. Dumenco, and C. Donovan.
  Human CD34(+) hematopoietic progenitors have low, cytokine- unresponsive O-6-alkylguanine-DNA alkyltransferase and are sensitive to O-6-benzylguanine plus BCNU. Blood 88: 1649-1655, 1996.
64.   Chinnasamy, N., J.A. Rafferty, I. Hickson, L.S. Lashford, S.J. Longhurst, N. Thatcher, G.P. Margison, T.M. Dexter, and L.J. Fairbairn.
  Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene Therapy 5: 842-847, 1998.
65.   Hickson, I., L.J. Fairbairn, N. Chinnasamy, L.S. Lashford, N. Thatcher, Margison, GP, T.M. Dexter, and J.A. Rafferty.
  Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene Therapy 5: 835-841, 1998.
66.   Wedge, S.R., J.K. Porteus, B.L. May, and E.S. Newlands.
  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. British Journal of Cancer 73: 482-490, 1996.
67.   Fairbairn, L.J., A.J. Watson, J.A. Rafferty, R.H. Elder, and G.P. Margison.
  O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Experimental Hematology 23: 112-116, 1995.
68.   Hickson, I., L.J. Fairbairn, N. Chinnasamy, T.M. Dexter, G.P. Margison, and J.A. Rafferty.
  Protection of mammalian cells against chloroethylating agent toxicity by an O-6-benzylguanine-resistant mutant of human O-6-alkylguanine- DNA alkyltransferase. Gene Therapy 3: 868-877, 1996.
69.   Berg, S.L., D.J. Murry, C.L. McCully, K. Godwin, and F.M. Balis.
  Pharmacokinetics of O-6-benzylguanine and its active metabolite 8- oxo-O-6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O-6-benzylguanine in the nonhuman primate. Clinical Cancer Research 4: 2891-2894, 1998.
70.   Dolan, M.E.
  Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. Advanced Drug Delivery Reviews 26: 105-118, 1997.
71.   Levati, L., G. Marra, T. Lettieri, S. DATRI, P. Vernole, L. Tentori, P.M. Lacal, E. Pagani, E. Bonmassar, J. Jiricny, and G. Graziani.
  Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T- cell leukemia line tolerant to methylating agents. Genes Chromosomes & Cancer 23: 159-166, 1998.
72.   Wedge, S.R., J.K. Porteous, and E.S. Newlands.
  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. British Journal of Cancer 74: 1030-1036, 1996.
73.   Liu, L., S. Markowitz, and S.L. Gerson.
  Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Research 56: 5375-5379, 1996.
74.   D'Atri, S., L. Tentori, P.M. Lacal, G. Graziani, E. Pagani, E. Benincasa, G. Zambruno, E. Bonmassar, and J. Jiricny.
  Involvement of the mismatch repair system in temozolomide-induced apoptosis. Molecular Pharmacology 54: 334-341, 1998.
75.   Fink, D., S. Aebi, and S.B. Howell.
  The role of DNA mismatch repair in drug resistance. [Review] [75 refs]. Clinical Cancer Research 4: 1-6, 1998.
76.   Friedman, H.S., R.E. McLendon, T. Kerby, M. Dugan, S.H. Bigner, A.J. Henry, D.M. Ashley, J. Krischer, S. Lovell, K. Rasheed, F. Marchev, A.J. Seman, I. Cokgor, J. Rich, E. Stewart, O.M. Colvin, J.M. Provenzale, D.D. Bigner, M.M. Haglund, A.H. Friedman, and P.L. Modrich.
  DNA mismatch repair and O-6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology 16: 3851-3857, 1998.
77.   Lee, S.E., S.P. Johnson, L.P. Hale, J. Li, N. Bullock, H. Fuchs, A. Friedman, R. McLendon, D.D. Bigner, P. Modrich, and H.S. Friedman.
  Analysis of DNA mismatch repair proteins in human medulloblastoma. Clinical Cancer Research 4: 1415-1419, 1998.
78.   Satoh, M.S. and T. Lindahl.
  Role of poly(ADP-ribose) formation in DNA repair. Nature (Lond) 356: 356-358, 1992.
79.   Tisdale, M.J.
  Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. British Journal of Cancer 52: 789-792, 1985.
80.   Tentori, L., P.M. Lacal, E. Benincasa, D. Franco, I. Faraoni, E. Bonmassar, and G. Graziani.
  Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. Journal of Pharmacology & Experimental Therapeutics 285: 884-893, 1998.
81.   Boulton, S., L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, B.T. Golding, and B.W. Durkacz.
  Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. British Journal of Cancer 72: 849-856, 1995.
82.   Griffin, R.J., S. Srinivasan, K. Bowman, A.H. Calvert, N.J. Curtin, D.R. Newell, L.C. Pemberton , and B.T. Golding.
  Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). Journal of Medicinal Chemistry 41: 5247-5256, 1998.
83.   Bowman, K.J., A. White, B.T. Golding, R.J. Griffin, and N.J. Curtin.
  . Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. British Journal of Cancer 78: 1269-1277, 1998.
84.   Boulton, S., S. Kyle, and B.W. Durkacz.
  Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair. British Journal of Cancer 76: 845-851, 1997.
85.   Brindley, C.J., P. Antoniw, and E.S. Newlands.
  Plasma and tissue disposition of mitozomide in mice. British Journal of Cancer 53: 91-97, 1986.
86.   Devineni, D., A. Klein-Szanto, and J.M. Gallo.
  Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Research 56: 1983-1987, 1996.
87.   Ganong, W.F
  Reviews of Medical Physiology. Lange Medical Publications, 1985, p. 500
88.   McVie, J.G.
  The therapeutic challenge of gliomas. [Review] [37 refs]. European Journal of Cancer 29A: 936-939, 1993.
89.   Newlands, E.S., G.R. Blackledge, J.A. Slack, and et al
  Phase I clinical trials of mitozolomide (CCRG 81010; M&B 39565; NSC 353451). Cancer Treatment Reports 69: 801-805, 1985.
90.   Tentori, L., C. Leonetti, and A. Aquino.
  Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of alpha-6 integrin phosphorylation. European Journal of Cancer 31A: 746-754, 1995.
91.   Baltuch, G.H., N.P. Dooley, J.G. Villemure, and V.W. Yong.
  . Protein kinase C and growth regulation of malignant gliomas. Can J Neurol Sci 22: 264-271, 1995.
92.   Hepburn, P.A. and M.J. Tisdale.
  Antitumour imidazotetrazines--XXIV. Growth suppression by DNA from cells treated with imidazotetrazinones. Biochemical Pharmacology 41: 339-343, 1991.
93.   Wedge, S.R., J.K. Porteous, and E.S. Newlands.
  Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemotherapy & Pharmacology 40: 266-272, 1997.
94.   Plowman, J., W.R. Waud, A.D. Koutsoukos, L.V. Rubinstein, T.D. Moore, and M.R. Grever.
  Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Research 54: 3793-3799, 1994.
95.   Friedman, H.S., M.E. Dolan, A.E. Pegg, S. Marcelli, S. Keir, J.J. Catino, Bigner, DD, and S.C. Schold, Jr.
  Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853-2857, 1995.
96.   Wedge, S.R. and E.S. Newlands.
  O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. British Journal of Cancer 73: 1049-1052, 1996.
97.   Pera, M.F., B. Koberle, and J.R. Masters.
  Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide [see comments]. British Journal of Cancer 71: 904-906, 1995.
98.   Raymond, E., E. Izbicka, H. Soda, S.L. Gerson, M. Dugan, and D.D. VonHoff.
  Activity of temozolomide against human tumor colony-forming units. Clinical Cancer Research 3: 1769-1774, 1997.
99.   Bobola, M.S., S.H. Tseng, A. Blank, M.S. Berger, and J.R. Silber.
  Role of O-6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clinical Cancer Research 2: 735-741, 1996.
100.   Wedge, S.R., J.K. Porteous, M.G. Glaser, K. Marcus, and E.S. Newlands.
  In vitro evaluation of temozolomide combined with X-irradiation. Anti-Cancer Drugs 8: 92-97, 1997.
101.   Bunn, P.A., S.J. Hoffman, D. Norris, L.E. Golitz, and J.L. Aeling.
  Systemic therapy of cutaneous T-cell lymphomas (mycosis-fungoides and the the Sezary-syndrome). Annals of Internal Medicine 121: 592-602, 1994.
102.   Woll, P.J., D. Crowther, P.W. Johnson, M. Soukop, P.G. Harper, M. Harris, M.H. Brampton, and E.S. Newlands.
  Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. British Journal of Cancer 72: 183-184, 1995.
103.   Franchi, A., G. Papa, S. D'Atri, D. Piccioni, M. Masi, and E. Bonmassar.
  Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study. Haematologica 77: 146-150, 1992.
104.   Piccioni, D., S. D'Atri, G. Papa, T. Caravita, A. Franchi, E. Bonmassar, and G. Graziani.
  Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. Journal of Chemotherapy 7: 224-229, 1995.
105.   D'Atri, S., D. Piccioni, A. Castellano, V. Tuorto, A. Franchi, K. Lu, N. Christiansen, S. Frankel, Y.M. Rustum, and G. Papa.
  Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Annals of Oncol 6: 389-393, 1995.
106.   Carter, C.A., W.R. Waud, and J. Plowman.
  Responses of human melanoma, ovarian, and colon tumour xenografts in nude mice to oral temozolomide. Proc.Amer.Assoc.Cancer Res. 35: 297-(Abstract 1769)1994.
107.   Moore, M.J., R. Feld, D. Hedley, A. Oza, and L.L. Siu.
  . A phase II study of Temozolomide in advanced untreated pancreatic cancer. Investigational New Drugs 16: 77-79, 1998.
108.   Di Palma, M., J.M. Vannetzel, H. Bensadoun, G. Benoit, E. Cvitkovic, and P. Boyer.
  Phase II study of temozolomide (Tem) in metastatic renal cell carcinoma (mRCC). Proc Amer Soc Clin Oncol 17: (Abstract 1271)1998.
109.   Chan, A.T., T.W. Leung, W.H. Kwan, T.S. Mok, W. Yeo, M. Lai, and P.J. Johnson.
  Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. Cancer Chemotherapy & Pharmacology 42: 247-249, 1998.
110.   Abrams, J.S., T.D. Moore, and M. Friedman
  New chemotherapeutic agents for breast cancer. [Review] [130 refs]. Cancer 74: 1164-1176, 1994.
111.   Eckardt, J.R.
  New approaches to the treatment of advanced breast cancer. Anti-Cancer Drugs 7: 41-46, 1996.
112.   Findlay, M., S.J. Clarke, M. Boyer, A. Sullivan, M. Dugan, P. Statkevich, L. Reyderman, N. Teriana, and K. Cox.
  Temodal (R) (temozolomide;TMZ) in patients with hepatocellular carcinoma (HCC), cirrhosis and portal hypertension: a phase II/pharmacokinetic (PK) study. Proceedings of the American Society of Clinical Oncology 17: (Abstract 923)1998.
113.   Kirkwood, J.M., S.S. Agarwala, B. Diaz, S. Donnelly, P. Statkevich, and M. Dugan.
  Phase I study of temozolomide in combination with interferon alfa-2b in metastatic malignant melanoma. Proceedings of the American Society of Clinical Oncology 16: 491a-(Abstract 1767)1997.
114.   Bleehen, N.M., E.S. Newlands, S.M. Lee, N. Thatcher, P. Selby, A.H. Calvert, G.J. Rustin, M. Brampton, and M.F.G. Stevens.
  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. Journal of Clinical Oncology 13: 910-913, 1995.
115.   Middleton, M.R., J.M. Lunn, C. Morris, G. Rustin, S.R. Wedge, M.H. Brampton, M.J. Lind, S.M. Lee, D.R. Newell, N.M. Bleehen, E.S. Newlands , A.H. Calvert, G.P. Margison, and N. Thatcher.
  O-6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. British Journal of Cancer 78: 1199-1202, 1998.
116.   Smith, D.C., S.L. Gerson, L.L. Liu, S. Donnelly, R. Day, D.L. Trump, and J.M. Kirkwood.
  Carmustine and streptozocin in refractory melanoma: An attempt at modulation of O-6-alkylguanine-DNA-alkyltransferase. Clinical Cancer Research 2: 1129-1134, 1996.
117.   Myatt, N., I.A. Cree, C.M. Kurbacher, A.J. Foss, J.L. Hungerford, and P.N. Plowman.
  The ex vivo chemosensitivity profile of choroidal melanoma. Anti-Cancer Drugs 8: 756-762, 1997.
118.   Anderson, C.M., A.C. Buzaid, and S.S. Legha.
  Systemic treatments for advanced cutaneous melanoma. [Review] [55 refs]. Oncology 9: 1149-1158, 1167.
119.   Newlands, E.S., G.R. Blackledge, J.A. Slack, G.J. Rustin, D.B. Smith, N.S. Stuart, C.P. Quarterman, R. Hoffman, M.F.G. Stevens, and M.H. Brampton.
  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). British Journal of Cancer 65: 287-291, 1992.
120.   O'Reilly, S.M., E.S. Newlands, M.G. Glaser, M. Brampton, J.M. Rice-Edwards, R.D. Illingworth, P.G. Richards, C. Kennard, I.R. Colquhoun, and P. Lewis.
  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [published erratum appears in Eur J Cancer 1993;29A(10):1500]. Eur J Canc 29A: 940-942, 1993.
121.   Newlands, E.S., S.M. O'Reilly, M.G. Glaser, M. Bower, H. Evans, C. Brock, M.H. Brampton, I. Colquhoun, P. Lewis, J.M. Rice-Edwards, R.D. Illingworth, and P.G. Richards.
  The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Canc 32A: 2236-2241, 1996.
122.   Bower, M., E.S. Newlands, N.M. Bleehen, M. Brada, R.J. Begent, H. Calvert, I. Colquhoun, P. Lewis, and M.H. Brampton .
  Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemotherapy & Pharmacology 40: 484-488, 1997.
123.   Porteous, J.K., C. Brock, H. Evans, and M.H. Brampton.
  Temozolomide: drug scheduling in vivo and in combination with radiation. Proceedings of the American Society of Clinical Oncology 16: Abstract 1403,1997.
124.   Dhodapkar, M., J. Rubin, J.M. Reid, P.A. Burch, H.C. Pitot, J.C. Buckner, M.M. Ames, and V.J. Suman.
  Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clinical Cancer Research 3: 1093-1100, 1997.
125.   Brock, C.S., J.C. Matthews, G. Brown, S. Osman, S.K. Luthra, F. Brady, E.S. Newlands, and P. Price.
  Temozolomide uptake in human astrocytomas demonstrated in vivo. Proceedings of the American Society of Clinical Oncology 16: 1997.(Abstract)
126.   Eckhardt, S.G., Y. Atkins, S.S. Agarwala, J.R. Eckardt, S. Diab, M. Dugan, P. Reidenberg, P. Statkevich, K. Forral, M. Kraynak, D.D. Von Hoff, and E.K. Rowinsky.
  A phase I study of temozolomide combined with cisplatin (CDDP) in patients with advanced cancer. Proceedings of the American Society of Clinical Oncology 16: 236a-(Abstract 830)1997.
127.   Levin, V., A. Yung, M. Prados, M. Poisson, S. Rosenfeld, M. Brada, H. Friedman, R. Albright, J. Olson, J. Bruner, N. Yue, M. Dugan, and & Temodal Brain Tumor Group.
  Phase II study of temodal (R) (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proceedings of the American Society of Clinical Oncology 16: (Abstract 1370)1997.
128.   Brock, C.S., E.S. Newlands, S.R. Wedge, M. Bower, H. Evans, L. Colquhoun, M. Roddie, M. Glaser, M.H. Brampton, and G.S. RUSTIN.
  Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Research 58: 4363-4367, 1998.
129.   Nicholson, H.S., M. Krailo, M.M. Ames, N.L. Seibel, J.M. Reid, W. Liu-Mares, L.G. Vezina, A.G. Ettinger, and G.H. Reaman.
  Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. Journal of Clinical Oncology 16: 3037-3043, 1998.
130.   Brem, H., R. Parker, and S. Zonis.
  In vitro synergistic activity of L-buthionine-S,R-sulfoximine (BSO) with BCNU and temozolomide on human glioblastoma multiforme. Proceedings of the American Society of Clinical Oncology 17: (Abstract 763)1998.
131.   Estlin, E.J., L. Lashford, S. Ablett, L. Price, R. Gowing, A. Gholkar, Kohler, I.J. Lewis, B. Morland, C.R. Pinkerton, M.C. Stevens, M. Mott, R. Stevens, D.R. Newell, D. Walker, C. Dicks-Mireaux, H. McDowell, P. Reidenberg, P. Statkevich, A. Marco, V. Batra, M. Dugan, and A.D. Pearson.
  Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. British Journal of Cancer 78: 652-661, 1998.
132.   Vaupel, P., F. Kallinowski, and P. Okunieff.
  Blood flow, oxygen and nutrient supply, and metabolic environment of human tumors: a review. Cancer Research 49: 6449-6465, 1989.
133.   Arnold, D.L., E.A. Shoubridge, W. Feindel, and J.G. Villemure.
  Metabolic changes in cerebral gliomas within hours of treatment with intrarterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy. Canadian Journal of Neurological Sciences 14: 570-575, 1987.
134.   Osoba, D., V. Levin, W.K.A. Yung, M. Brada, M. Prados, R. Albricht, J. Olsen, C.S.W. Weng, and M. Dugan.
  Health-related quality-of-life (HRQL) benefits in patients with recurrent anaplastic astrocytoma (AA) treated with temozolomide (TEM). American Society of Clinical Oncology 17: 1998.
135.   Brada, M., S. Moore, I. Judson, and et al.
  A phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer. Proc.Amer.Assoc.Cancer Res. 14: 470- (Abstract 1521),1995.
136.   Friedman, H.S., S.P. Johnson, Q. Dong, S.C. Schold, B.K. Rasheed, S.H. Bigner, F. Ali-Osman, E. Dolan, O.M. Colvin, P. Houghton, G. Germain, J.T. Drummond, S. Keir, S. Marcelli, D.D. Bigner , and P. Modrich.
  Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft [published erratum appears in Cancer Res 1997 Nov 1;57(21):4973]. Cancer Research 57: 2933-2936, 1997.
137.   Reni, M., A.J.M. Ferreri, C. Landoni, and E. Villa.
  . Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. Journal of the National Cancer Institute 92: 575-576, 2000.
138.   Batchelor, T.
  Temozolomide for malignant brain tumours. Lancet 355: 1115-1116, 2000.
139.   Griffiths, J.R. and J.D. Glickson.
  Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. Advanced Drug Delivery Reviews 41: 75-89, 2000.
140.   Clemons, M., A. Watson, A. Howell, J. Chang, C. Heyworth, B. Lord, N. Testa, T.M. Dexter, and G. Margison.
  Macrophage inflammatory protein 1 alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. Clinical Cancer Research 6: 966-970, 2000.
141.   Houghton, P.J. and T.P. Brent.
  Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clinical Cancer Research 6: 998-1007, 2000.
142.   Newlands, E.S., G.R.P. Blackledge, J.A. Slack, G.J. Rustin, D.B. Smith, N.S. Stuart, C.P. Quarterman, R. Hoffman, M.F.G. Stevens, M.H. Brampton, and A.C. GIBSON.
  Antitumour imidazotetrazines. 26.Phase-1 trial of temozolomide (CCRG-81045,M-And-B 39831,NSC-362856). British Journal of Cancer 65: 287-291, 1992.
143.   Reese, J.S., O.N. Koc, and S.L. Gerson.
  Human mesenchymal stem cells provide stromal support for efficient CD34(+) transduction. Journal of Hematotherapy & Stem Cell Research 8: 515-523, 1999.
144.   Diana, P., P. Barraja, A. Lauria, Almerico.A.M., G. Dattolo, and G. Cirrincione.
  Pyrrolo[2,1-d][1,2,3,5]tetrazines, a new class of azolotetrazines related to the antitumor drug temozolomide. Synthesis-Stuttgart 2082-2086, 1999.
145.   Diana, P., P. Barraja, A. Lauria, A.M. Almerico, G. Cirrincione, A.G. Loi, C. Musiu, A. Pani, P. La Colla, and M.E. Marongiu.
  2-triazenopyrroles:synthesis and biological activity. European Journal of Medicinal Chemistry 34: 353-360, 1999.
146.   Reidenberg, P., P. Statkevich, I. Judson, S. Moore, D. Cutler, V. Batra, M. Dugan, and M. Brada.
  Effect of food on the oral, bioavailability of temozolomide, a new chemotherapeutic agent. CLINICAL PHARMACOLOGY & THERAPEUTICS 59: II441996.
147.   Faraoni, I., M. Turriziani, E. Bonmasssar, L. DeVecchis, and G. Graziani.
  Development of a novel in vitro chemosensitivity assay: Telomerase as a possible marker of tumor cell survival. Journal of Chemotherapy 8: 394-398, 1996.
148.   Curtin, N.J., S. Kyle, L.Z. Wang, B.W. Durkacz, A.J. White, S. Srinivasan, R.J. Griffin, B.T. Golding, D.R. Newell, A.H. Calvert, K. Maegley, and Z. Hostomsky.
  Potentiation of temozolomide and topetecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) poymerase (PARP) inhibitors. (Meeting Abstract). Clinical Cancer Research 5: 5201999.
149.   Arance, A., M.R. Middleton, and N. Thatcher.
  Phase II trial of 4-hourly temozolomide (TMZ) in advanced malignant melanoma (MM) (Meeting Abstract). Eur J Canc 35: 15091999.
150.   Brock, C.S., J.C. Matthews, G. Brown, S. Osman, H. Evans, E.S. Newlands, and P. Price.
  Response to temozolomide (TEM) in recurrent high grade gliomas (HGG) is related to tumour drug concentration. Annals of Oncology 9: 6671998.
151.   Britten, C.D., E.K. Rowinsky, S.S. Agarwala, S.D. Baker, J. Eckardt, S. Diab, M. Dugan, P. Reidenberg, P. Statkevich, A. Marco, A. Loomba, K. Forral, M. Kraynak, D.D. VonHoff, and S.G. Eckhardt.
  A phase I safety and pharmacokinetic (PK) study of temozolomide in combination with cisplatin. Annals of Oncology 9: 4421998.
152.   Hammond, L., J. Eckardt, J. Kuhn, J. Rizzo, T. Johnson, M. VillalonaCalero, L. Smith, R. Drengler, L. Campbell, D. VonHoff, and E. Rowinsky.
  Phase I and pharmacokinetic (PK) trial of sequences of BCNU and temozolomide (TMZ) in patients with solid neoplasms. Annals of Oncology 9: 4411998.
153.   Raymond, E., E. Izbicka, H. Soda, S. Gerson, M. Dungan, and D. VonHoff.
  Effects of temozolomide against human tumor using the human tumor cloning assay. Annals of Oncology 9: 1451998.
154.   Anonymous.
  Positive clinical data from temozolomide trials presented at European Oncology Meeting. DRUG NEWS & PERSPECTIVES 11: 4271998.
155.   Agarwala, S.S., A. Reyderman, P. Statkevich, U. Fraass, A. Loomba, L.L. Stover, and J.M. Kirkwood.
  Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Annals of Oncology 9: 6591998.
156.   Chowdhury, S.K., D. Laudicina, N. Blumenkrantz, M. Wirth, and K.B. Alton .
  An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma. Journal of Pharmaceutical & Biomedical Analysis 19: 659-668, 1999.
157.   Yung, W.K., M.D. Prados, R. Yaya-Tur, S.S. Rosenfeld, M. Brada, H.S. Friedman, R. Albright, J. Olson, S.M. Chang, A.M. O'Neill, A.H. Friedman , J. Bruner, Yue, M. Dugan, S. Zaknoen, and V.A. Levin.
  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group [published erratum appears in J Clin Oncol 1999 Nov;17(11):3693]. Journal of Clinical Oncology 17: 2762-2771, 1999.
158.   Sullivan, D.C. and P.F. Swann.
  Synergistic action of temozolomide and thioguanine on glioblastoma xenografts.(Meeting Abstract). Brit Journal of Cancer 81: P161999.
159.   Brock, C.S., H. Young, S.M. O'Reilly, J. Matthews, S. Osman, H. Evans, Newlands, ES, and P.M. Price.
  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. British Journal of Cancer 82: 608-615, 2000.
160.   Middleton, M.R., J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher.
  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology 18: 158-166, 2000.
161.   Middleton, M.R., J. Kelly, S. Goodger, N. Thatcher, and G.P. Margison.
  Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemotherapy & Pharmacology 45: 15-20, 2000.
162.   Middleton, M.R., J. Kelly, N. Thatcher, D.J. Donnelly, R.S. McElhinney, McMurry, TB, J.E. McCormick, and G.P. Margison.
  O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. International Journal of Cancer 85: 248-252, 2000.
163.   Hammond, L.A., J.R. Eckardt, S.D. Baker, S.G. Eckhardt, M. Dugan, K. Forral, P. Reidenberg, P. Statkevich, G.R. Weiss , D.A. Rinaldi, H.D. Von , Rowinsky, and EK.
  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. Journal of Clinical Oncology 17: 2604-2613, 1999.
164.   Delaney, C.A., L.Z. Wang, L.Z. Kyle, S. Srinivasan, A.W. White, N.J. Curtin, A.H. Calvert, B.W. Durkacz, and D.R. Newell.
  Potentiation of temozolomide and topetecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. (Meeeting Abstract). Brit Journal of Cancer 80: P621999.
165.   Hvizdos, K.M. and K.L. Goa.
  Temozolomide. CNS Drugs 12: 237-243, 1999.
166.   Alvino, E., R. Pepponi, E. Pagani, P.M. Lacal, C. Nunziata, E. Bonmassar, and S. D'Atri.
  O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity. Journal of Pharmacology & Experimental Therapeutics 291: 1292-1300, 1999.
167.   Miller, J.L.
  Oral temozolomide approved for refractory brain tumor [news]. American Journal of Health-System Pharmacy 56: 19101999.
168.   Brada, M., I. Judson, P. Beale, S. Moore, P. Reidenberg, P. Statkevich, Dugan, V. Batra, and D. Cutler.
  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. British Journal of Cancer 81: 1022-1030, 1999.
169.   Arrowsmith, J., S. Missailidis, and M.F. Stevens.
  Antitumour imidazotetrazines. Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing the minor groove. Anti-Cancer Drug Design 14: 205-217, 1999.
170.   Gander, M., S. Leyvraz, L. Decosterd, M. Bonfanti, C. Marzolini, F. Shen, D. Lienard, L. Perey, G. Colella, J. Biollaz, F. Lejeune, D. Yarosh, Belanich, and M. D'Incalci.
  Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Annals of Oncology 10: 831-838, 1999.
171.   Phillips, W.P.J. and S.L. Gerson.
  Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. Cancer Chemotherapy & Pharmacology 44: 319-326, 1999.
172.   Xu-Welliver, M., J. Leitao, S. Kanugula, W.J. Meehan, and A.E. Pegg.
  Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine. Biochemical Pharmacology 58: 1279-1285, 1999.
173.   Friedman, H.S.
  Temozolomide - A viewpoint. CNS Drugs 12: 2441999.
174.   Britten, C.D., E.K. Rowinsky, S.D. Baker, S.S. Agarwala, J.R. Eckardt, Barrington, S.G. Diab, L.A. Hammond, T. Johnson, M. Villalona-Calero, U. Fraass, P. Statkevich, H.D. Von, and S.G. Eckhardt.
  A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clinical Cancer Research 5: 1629-1637, 1999.
175.   Woll, P.J., I. Judson, S.M. Lee, S. Rodenhuis, O.S. Nielsen, J.M. Buesa, Lorigan, PC, S. Leyvraz, C. Hermans, G.M. van, and J. Verweij.
  Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 35: 410-412, 1999.
176.   Sampson, J.H., G.E. Archer, A.T. Villavicencio, R.E. McLendon, A.H. Friedman, W.R. Bishop, D.D. Bigner, and H.S. Friedman.
  Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research 5: 1183-1188, 1999.
177.   Avgeropoulos, N.G. and T.T. Batchelor.
  New treatment strategies for malignant gliomas. [Review] [126 refs]. Oncologist 4: 209-224, 1999.
178.   Paulsen, F., W. Hoffmann, G. Becker, C. Belka, M. Weinmann, J. Classen, R.D. Kortmann, and M. Bamberg.
  . Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. Journal of Cancer Research & Clinical Oncology 125: 411-418, 1999.
179.   Tentori, L., M. Turriziani, D. Franco, A. Serafino, L. Levati, R. Roy, E. Bonmassar, and G. Graziani.
  Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13: 901-909, 1999.
180.   Burton, E. and M. Prados
  New chemotherapy options for the treatment of malignant gliomas. [Review] [24 refs]. Current Opinion in Oncology 11: 157-161, 1999.
181.   Newlands, E.S
  Temozolomide - A viewpoint. CNS Drugs 12: 2451999.
182.   Lage, H. and M. Dietel.
  Involvement of the DNA mismatch repair system in antineoplastic drug resistance. [Review] [85 refs]. Journal of Cancer Research & Clinical Oncology 125: 156-165, 1999.
183.   Sankar, A., D.G. Thomas, and J.L. Darling.
  Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anti-Cancer Drugs 10: 179-185, 1999.
184.   Baker, S.D., M. Wirth, P. Statkevich, P. Reidenberg, K. Alton, S.E. Sartorius, M. Dugan, D. Cutler, V. Batra, L.B. Grochow, R.C. Donehower, and E.K. Rowinsky
  Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clinical Cancer Research 5: 309-317, 1999.
185.   Toft, N.J., D.J. Winton, J. Kelly, L.A. Howard, M. Dekker, R.H. te, Arends, MJ, A.H. Wyllie, G.P. Margison, and A.R. Clarke.
  Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proceedings of the National Academy of Sciences of the United States of America 96: 3911-3915, 1999
186.   Jean-Claude, B.J., A. Mustafa, Z. Damian, M.J. De, D.E. Vasilescu, R. Yen, T.H. Chan, and B. Leyland-Jones.
  Cytokinetics of a novel 1,2,3-triazene-containing heterocycle, 8-nitro-3-methyl-benzo-1,2,3,5-tetrazepin-4(3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3. Biochemical Pharmacology 57: 753-762, 1999.
187.   Boulton, S., S. Kyle, and B.W. Durkacz.
  Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20: 199-203, 1999.
188.   Reese, J.S., B.M. Davis, L. Liu, and S.L. Gerson.
  Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Clinical Cancer Research 5: 163-169, 1999.
189.   Howell, S.B. and D. Fink
  Genomic instability and drug resistance. Molecular Urology 2: 247-254, 1998.
190.   Claij, N. and R.H. te
  Microsatellite instability in human cancer: a prognostic marker for chemotherapy?. [Review] [137 refs]. Experimental Cell Research 246: 1-10, 1999.
191.   Liu, L., P. Taverna, C.M. Whitacre, S. Chatterjee, and S.L. Gerson.
  Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clinical Cancer Research 5: 2908-2917, 1999.
192.   Dolan, M.E., B.L. McRae, E. Ferries-Rowe, M. Belanich, S.G. van, Guitart, D. Pezen, T.M. Kuzel, and D.B. Yarosh.
  O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clinical Cancer Research 5: 2059-2064, 1999.
193.   Beale, P., I. Judson, S. Moore, P. Statkevich, A. Marco, D.L. Cutler, P. Reidenberg, and M. Brada.
  Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemotherapy & Pharmacology 44: 389-394, 1999.
194.   Ma, J., Z.L. Fei, A. Klein-Szanto, and J.M. Gallo.
  Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clinical & Experimental Metastasis 16: 559-568, 1998.
195.   Agarwala, S.S.
  Temozolomide, anovel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. The Oncologist 5: 144-151, 2000.
196.   Pegg, A.E.
  DNA repair pathways and cancer prevention. [Review] [64 refs]. Advances in Experimental Medicine & Biology 472: 253-267, 1999.
197.   Hillner, B.E., S. Agarwala, and M.R. Middleton.
  Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. Journal of Clinical Oncology 18: 1474-1480, 2000.
198.   O'Shaughnessy, J.A.
  Oral alkylating agents for breast cancer therapy. [Review] [27 refs]. Drugs 58 Suppl 3: 1-9, 1999.
199.   Middleton, M.R., P. Lorigan, J. Owen, L. Ashcroft, S.M. Lee, P. Harper, and N. Thatcher.
  A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British Journal of Cancer 82: 1158-1162, 2000.
200.   Silber, J.R., A. Blank, M.S. Bobola, S. Ghatan, D.D. Kolstoe, and M.S. Berger.
  O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clinical Cancer Research 5: 807-814, 1999.
201.   Shinkwin, A.E., W.J. Whish, and M.D. Threadgill .
  Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorganic & Medicinal Chemistry 7: 297-308, 1999.
202.   Koc, O.N., J.S. Reese, B.M. Davis, L. Liu, K.J. Majczenko, Gerson, and SL.
  DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Human Gene Therapy 10: 1021-1030, 1999.
203.   Chinot, O.L., S. Honore, M.F. Barrie, H. Dufour, D. Braguer, and F. Grisoli.
  Temodal (Temozolomide, TMZ) in second line treatment after PCV in oligodendroglial tumors. Proc Amer Soc Clin Oncol 19: : Abstract 614;2000.
204.   Jaeckle, K.A., W.A. Yung, M. Prados, and K.R. Hess.
  Phase II evaluation of temozolomide and 13-CIS retinoic acid (Isotretinoin;CRA) for the treatment of recurrent ANC progressive malignant gliomas (NABTC 98-03). Proc Amer Soc Clin Oncol 19: Abstract 629;2000.
205.   Stupp, R., S. Ostermann, P. Kraljevic, A. Dietrich, I. Pica, P. Maillard, C. Miralbell, J. Collao, J. Villemure, R.O. De Tribolet, R.O. Mirimanoff, and S. Leyvraz.
  Promising survival with concomitant and adjuvant temozolomide [TMZ] for newly diagnosed glioblastoma multiforme [GBM]. Proc Amer Soc Clin Oncol 19: Abstract 632;2000.
206.   Wurm, R.E., L. Roeschel, D. Scheffler, B. Sommer, A. Kaiser, M. Steingraeber, M. Fitzek, D. Geismar, M. Koerner, L. Schlenger, M. Stuschke, and V. Budach.
  Phase I-II study with continuous dose-escalated 21 day schedule temozolomide in recurrent high-grade glioma. Proc Amer Soc Clin Oncol 19: Abstract 634;2000.
207.   Abrey, L.E., J. Olson, D.Y. Boutros, M. Mack, A. Rodavitch, J.J. Raizer, and M.G. Malkin.
  A phase II study of temozolomide for recurrent brain metastases. Proc Amer Soc Clin Oncol 19: Abstract 643;2000.
208.   Brandes, A.A., M. Ermani, L. Pasetto, P. Amista, R. Scienza, and et al.
  Temozolomide (TMZ) in high grade gliomas (HGG) at second relapse: a phase II study. Proc Amer Soc Clin Oncol 19: Abstract 646;2000.
209.   Viviers, L., M. Brada, F. Hines, J. Britton, C. Abson, and S. Ashley
  A phase II trial of primary chemotherapy with temozolomide in patients with low-grade cerebral gliomas. Proc Amer Soc Clin Oncol 19: Abstract 648;2000.
210.   Resnick, G.D., S. Zaknoen, D.C. Roth, and et al.
  Temodar (temozolomide) in malignant glioma and advanced malignant melanoma: Results of two treatment access protocols. Proc Amer Soc Clin Oncol 19: Abstract 652;2000.
211.   Spagnolli, F., C. Boni, R. Gagliardi, and et al.
  Temozolomide as second line chemotherapy in the treatment of recurrent malignant gliomas. Proc Amer Soc Clin Oncol 19: : Abstract 653;2000.
212.   Friedman, A.H., I. Cokgor, S. Edwards, J. Rich, J.A. Quinn, and et al.
  Phase II treatment of anaplastic oligodendroglioma and low grade glioma with temozolomide. Proc Amer Soc Clin Oncol 19: Abstract 654;2000.
213.   Christodoulou, C., D. Bafaloukos, P. Kosmidis, and et al.
  Temozolomide (TMZ) in patients with brain metastases from solid tumors. A Hellenic Cooperative Oncology Group Study. Proc Amer Soc Clin Oncol 19: Abstract 665;2000.
214.   Colvin, O.M., I. Cokgor, S. Edwards, and et al.
  Phase I trials of gliadel plus CPT-11 or temodar. Proc Amer Soc Clin Oncol 19: Abstract 668;2000.
215.   Tolcher, A.W., S. Felton, S.L. Gerson, and et al.
  Persistent and marked inactivation of 0-6-alkylguanine-DNA alkyltransferase (AGAT), a mechanism of resistance to alkylators, with protracted low-dose oral schedules of temozolomide. Proc Amer Soc Clin Oncol 19: Abstract 680;2000.
216.   Denis, L.J., A. Tolcher, J.A. Figueroa, and et al.
  Protracted daily administration of temozolomide is feasible: A phase I and pharmacokinetic - pharmacodynamic study. Proc Amer Soc Clin Oncol 19: : Abstract 786;2000.
217.   Figueroa, J.A., A. Tolcher, L.J. Denis, and et al.
  Protracted cyclic administration of temozolomide is feasible; a phase I pharmacokinetic and pharmacodynamic study. Proc Amer Soc Clin Oncol 19: Abstract 868;2000.
218.   Volm, M., R. Gratz, A. Pavlick, and et al
  A phase I study of liposomal doxorubicin and temozolomide in patients with advanced cancer. Proc Amer Soc Clin Oncol 19: : Abstract 872;2000.
219.   Dumas, M.C., C.W. Ryan, M.E. Dolan, and et al.
  A phase II trial of oral temozolomide (TEM) with measurement of tumor O6-alkylguanine-DNA alkyltransferase (AGT) activity in patients (Pts) with metastatic renal cell cancer. Proc Amer Soc Clin Oncol 19: Abstract 1479;2000.
220.   Taub, R.N., M. Keohan, M. Plitsas, and R. Scheinmann.
  Phase II study of temozolomide in advanced sarcomas. Proc Amer Soc Clin Oncol 19: Abstract 2185;2000.
221.   Kersten, M., W. Boogerd, D. Batchelor, and et al.
  Combined immunotherapy with Gm-CSF, IL-2 and IFNalpha allows dose escalation of temozolomide with prevention of lymphocytopenia and brain metastases in metastatic malignant melanoma. Proc Amer Soc Clin Oncol 19: Abstract 2244;2000.
222.   Gibbs, P., S. O'Day, J. Richards, and et al.
  A multicenter phase II study of modified biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF. Proc Amer Soc Clin Oncol 19: Abstract 2255;2000.
223.   Arance, A., M.R. Middleton, P. Lorigan, and N. Thatcher.
  Three-arm phase II study of temozolomide (TMZ) in metastatic melanoma (MM): Preliminary results. Proc Amer Soc Clin Oncol 19: Abstract 2257;2000.
224.   Bafaloukos, D., H. Gogas, E. Briassoulis, and et al.
  Temozolomide (TEM) and docetaxel (D) as first line chemotherapy in patients with advanced melanoma. A phase II study of Hellenic Cooperative Oncology Group. Proc Amer Soc Clin Oncol 19: Abstract 2258;2000.
225.   Franke, W., N. Neumann, D. Richter-Hintz, and et al.
  Temozolomide - a promising agent in the therapy of brain metastases in malignant melanoma. Proc Amer Soc Clin Oncol 19: Abstract 2268A;2000.
226.   Preul, M.C., Z. Caramanos, J.G. Villemure, G. Shenouda, R. LeBlanc, A. Langleben, and D.L. Arnold.
  Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46: 306-318, 2000.
227.   Schold, S.C., J. Kuhn, S.M. Chang, and et al.
  A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium Study. Neuro-Oncology 2: 34-39, 2000.

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557